<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03649581</url>
  </required_header>
  <id_info>
    <org_study_id>7058</org_study_id>
    <nct_id>NCT03649581</nct_id>
  </id_info>
  <brief_title>Investigation of Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders</brief_title>
  <acronym>NeuroSplitsz</acronym>
  <official_title>Investigation of Clinical, Cognitive and Neurophysiological Markers, Possibly Specific of Two Subforms of Psychotic Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Strasbourg, France</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Strasbourg, France</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The current diagnostic criteria for schizophrenia and other psychotic disorders are&#xD;
      relatively broad and lack precision. Therefore, distinct diseases may be grouped together&#xD;
      under the same diagnostic category, although these diseases may differ according to their&#xD;
      clinical expression, prognosis and perhaps their physiopathological causes.&#xD;
&#xD;
      We think that identifying subforms of psychotic disorders that are more homogeneous will&#xD;
      better enable to understand their respective physiopathological causes and find personalized&#xD;
      treatments.&#xD;
&#xD;
      This study will compare two subforms of psychotic disorders that have been clinically&#xD;
      distinguished in the 1970s. These phenotypes have however not been validated yet using&#xD;
      scientific investigations.&#xD;
&#xD;
      Using clinical assessments, cognitive evaluations and neurophysiological measures (fMRI)&#xD;
      investigating the domains of affect and psychomotoricity , we expect that these two subforms&#xD;
      will differ on their clinical, cognitive and neurophysiological characteristics, namely:&#xD;
      hebephrenia will be associated with deficits on the affect markers , and respect&#xD;
      psychomotoricity (catatonia scales, tests assessing movement planification) whereas the&#xD;
      opposite pattern will be observed for periodic catatonia.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 28, 2019</start_date>
  <completion_date type="Anticipated">February 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Index of affect</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Compare two groups of markers relating respectively to affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Index of psychomotoricity</measure>
    <time_frame>6 months after inclusion</time_frame>
    <description>Compare two groups of markers relating to psychomotricity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">84</enrollment>
  <condition>Schizophrenia</condition>
  <arm_group>
    <arm_group_label>patient with schizophrenia and periodic catatonia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>patient with schizophrenia and hebephrenia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>compare the two groups of schizophrenic patients</intervention_name>
    <description>Compare two groups of markers relating respectively to psychomotricity and affectivity in two subforms of schizophrenia: periodic catatonia and hebephrenia in order to highlight a possible double dissociation:&#xD;
abnormalities of markers related to affectivity in Hebephrenia (with preservation of these markers in periodic catatonia),&#xD;
abnormalities of markers related to psychomotricity in periodic catatonia (with markers of these tests in Hebephrenia).</description>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_label>patient with schizophrenia and hebephrenia</arm_group_label>
    <arm_group_label>patient with schizophrenia and periodic catatonia</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>compare the two groups of schizophrenic patients versus volunteers</intervention_name>
    <description>compare the results of the schizophrenic patient group with healthy volunteers</description>
    <arm_group_label>healthy volunteers</arm_group_label>
    <arm_group_label>patient with schizophrenia and hebephrenia</arm_group_label>
    <arm_group_label>patient with schizophrenia and periodic catatonia</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  for both patients and controls&#xD;
&#xD;
          -  male or female willing to participate and who have signed up the legal document&#xD;
&#xD;
          -  under the protection of health insurance for patients only&#xD;
&#xD;
          -  schizophrenia or schizo-affective disorder according to the DSM-5 criteria&#xD;
&#xD;
          -  periodic catatonia or hebephrenia accordin to WKL classification&#xD;
&#xD;
          -  clinically stable for at least 2 months&#xD;
&#xD;
          -  in or out patients for controls only&#xD;
&#xD;
          -  no psychiatric history&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  for both patients and controls&#xD;
&#xD;
          -  current severe or unstable somatic illness&#xD;
&#xD;
          -  neurological history (epilepsia, brain injury, brain surgery…)&#xD;
&#xD;
          -  current substance use disorder (DSM-5)&#xD;
&#xD;
          -  current major depressive disorder (DSM-5)&#xD;
&#xD;
          -  mental retardation (IQ &lt; 70)&#xD;
&#xD;
          -  pregnancy, breast feeding&#xD;
&#xD;
          -  current legal control&#xD;
&#xD;
          -  contra-indication for fMRI for controls only psychotropic intake during the last 3&#xD;
             weeks&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Fabrice BERNA, MD</last_name>
    <phone>03 88 11 64 62</phone>
    <email>fabrice.berna@chru-strasbourg.fr</email>
  </overall_contact>
  <location>
    <facility>
      <name>Service de Psychiatrie I, Hôpital Civil, Hôpitaux Universitaires de Strasbourg</name>
      <address>
        <city>Strasbourg</city>
        <zip>67091</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fabrice BERNA, MD</last_name>
      <phone>33388116462</phone>
      <email>fabrice.berna@chru-strasbourg.fr</email>
    </contact>
    <investigator>
      <last_name>Fabrice BERNA, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jack FOUCHER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julie CLAUSS, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Olivier MAINBERGER, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>August 21, 2018</study_first_submitted>
  <study_first_submitted_qc>August 27, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">August 28, 2018</study_first_posted>
  <last_update_submitted>September 13, 2021</last_update_submitted>
  <last_update_submitted_qc>September 13, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 14, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Schizophrenia</mesh_term>
    <mesh_term>Mental Disorders</mesh_term>
    <mesh_term>Psychotic Disorders</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

